Immune reconstitution inflammatory syndrome in HIV-infected patients
TLDR
An overview of clinical and epidemiological features of HIV-associated IRIS, current understanding of pathophysiological mechanisms, available therapy, and preventive strategies, and a particular focus on three important pathogen-associated forms.Abstract:
Access to antiretroviral therapy (ART) is improving worldwide. Immune reconstitution inflammatory syndrome (IRIS) is a common complication of ART initiation. In this review, we provide an overview of clinical and epidemiological features of HIV-associated IRIS, current understanding of pathophysiological mechanisms, available therapy, and preventive strategies. The spectrum of HIV-associated IRIS is described, with a particular focus on three important pathogen-associated forms: tuberculosis-associated IRIS, cryptococcal IRIS, and Kaposi’s sarcoma IRIS. While the clinical features and epidemiology are well described, there are major gaps in our understanding of pathophysiology and as a result therapeutic and preventative strategies are suboptimal. Timing of ART initiation is critical to reduce IRIS-associated morbidity. Improved understanding of the pathophysiology of IRIS will hopefully enable improved diagnostic modalities and better targeted treatments to be developed.read more
Citations
More filters
Journal ArticleDOI
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
Brinda Emu,Jeffrey Fessel,Shannon Schrader,Princy Kumar,Gary Richmond,Sandra Win,Steven Weinheimer,Christian Marsolais,Stanley Lewis +8 more
TL;DR: In patients with MDR HIV‐1 infection who had advanced disease and limited treatment options, ibalizumab had significant antiviral activity during a 25‐week study and in vitro testing identified 9 patients who had a lower degree of susceptibility to ibalIZumab than at baseline.
Journal ArticleDOI
Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives
Laurent Abel,Laurent Abel,Laurent Abel,Jacques Fellay,Jacques Fellay,David W. Haas,David W. Haas,Erwin Schurr,Geetha Srikrishna,Michael E. Urbanowski,Nimisha Chaturvedi,Nimisha Chaturvedi,Sudha Srinivasan,Daniel H. Johnson,William R. Bishai +14 more
TL;DR: The current understanding of the contribution of host genetics to disease susceptibility and to drug treatment is assessed, strongly indicating the need for larger global studies that investigate both common and under-represented rare variants to develop new approaches to combat the disease.
Journal ArticleDOI
Can differentiated care models solve the crisis in HIV treatment financing? Analysis of prospects for 38 countries in sub-Saharan Africa.
TL;DR: This work model the potential reduction in facility‐level costs and number of health workers needed when implementing two types of DCMs while attempting to reach 90‐90‐90 targets in 38 sub‐Saharan African countries from 2016 to 2020.
Journal ArticleDOI
The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment.
Esmé Jansen van Vuren,Stephan F. Steyn,Christiaan B. Brink,Marisa Möller,Francois P. Viljoen,Brian H. Harvey +5 more
TL;DR: In this paper, a review of the relationship between severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection and psychiatric diseases is presented, with an evident link between corona virus infections and various central and peripheral nervous system manifestations.
Journal ArticleDOI
Opportunistic infections and immune reconstitution inflammatory syndrome in HIV-1-infected adults in the combined antiretroviral therapy era: a comprehensive review.
Christian Manzardo,Alberto C. Guardo,Emilio Letang,Montserrat Plana,José M. Gatell,José M. Miró +5 more
TL;DR: This review updates current knowledge about the incidence, diagnostic criteria, risk factors, clinical manifestations, and management of opportunistic infections and immune reconstitution inflammatory syndrome in the combined antiretroviral treatment era.
References
More filters
Journal ArticleDOI
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
Frank J. Palella,Kathleen M. Delaney,Anne C. Moorman,Mark O. Loveless,Jack Fuhrer,Glen A. Satten,Diane J. Aschman,Scott D. Holmberg +7 more
TL;DR: The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.
Journal ArticleDOI
Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
TL;DR: A study was conducted to evaluate the impact of protease inhibitors on the rates of selected opportunistic processes and mortality in patients with AIDS and found similar results.
Journal ArticleDOI
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.
John R. Perfect,William E. Dismukes,Françoise Dromer,David L. Goldman,John R. Graybill,Richard J. Hamill,Thomas S. Harrison,Robert A. Larsen,Olivier Lortholary,Olivier Lortholary,Minh Hong Nguyen,Peter G. Pappas,William G. Powderly,Nina Singh,Jack D. Sobel,Tania C. Sorrell +15 more
TL;DR: Emphasis has been placed on potential complications in management of cryptococcal infection, including increased intracranial pressure, immune reconstitution inflammatory syndrome (IRIS), drug resistance, and cryptococcomas.
Journal ArticleDOI
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.
Paula Braitstein,Mwg Brinkhof,François Dabis,Mauro Schechter,Andrew Boulle,Paolo G. Miotti,Robin Wood,Christian Laurent,Eduardo Sprinz,Catherine Seyler,David R. Bangsberg,Eric Balestre,Jonathan A C Sterne,Margaret T May,Matthias Egger +14 more
TL;DR: Patients starting HAART in resource-poor settings have increased mortality rates in the first months on therapy, compared with those in developed countries, and timely diagnosis and assessment of treatment eligibility, coupled with free provision of HAART might reduce this excess mortality.
Journal ArticleDOI
Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
Salim S. Abdool Karim,Kogieleum Naidoo,Anneke Grobler,Nesri Padayatchi,Cheryl Baxter,Andy Gray,Tanuja N. Gengiah,Sheila Bamber,Aarthi Singh,M. Khan,Jacqueline Pienaar,Wafaa. El-Sadr,Gerald Friedland,Quarraisha Abdool Karim +13 more
TL;DR: The initiation of antiretroviral therapy during tuberculosis therapy significantly improved survival and provides further impetus for the integration of tuberculosis and HIV services.
Related Papers (5)
Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings.
Graeme Meintjes,Stephen D. Lawn,Stephen D. Lawn,Fabio Scano,Gary Maartens,Martyn A. French,William Worodria,Julian Elliott,David M Murdoch,Robert J. Wilkinson,Robert J. Wilkinson,Robert J. Wilkinson,Catherine Seyler,Laurence John,Maarten F. Schim van der Loeff,Peter Reiss,Lut Lynen,Edward N. Janoff,Charles F. Gilks,Robert Colebunders,Robert Colebunders +20 more
Immune restoration disease after antiretroviral therapy.
Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions
Lewis J. Haddow,Lewis J. Haddow,Robert Colebunders,Robert Colebunders,Graeme Meintjes,Stephen D. Lawn,Stephen D. Lawn,Julian Elliott,Julian Elliott,Yukari C. Manabe,Yukari C. Manabe,Paul R. Bohjanen,Somnuek Sungkanuparph,Philippa Easterbrook,Philippa Easterbrook,Martyn A. French,Martyn A. French,David R. Boulware +17 more